

## VIRALEZE™ launches in Europe

**Melbourne, Australia; 6 May 2021:** Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that VIRALEZE™ antiviral nasal spray is now available for purchase by consumers in Europe via Starpharma's [www.viraleze.co](http://www.viraleze.co) webstore.

VIRALEZE™ is already available in the UK through [LloydsPharmacy's](http://LloydsPharmacy.com) 1,400 stores and online and is expected to be available via independent UK pharmacies later this month.

VIRALEZE™ is a broad spectrum antiviral nasal spray that contains astodrimmer sodium (SPL7013), which is virucidal, irreversibly inactivating >99.9% of coronavirus/SARS-CoV-2 within one minute<sup>1</sup>. These antiviral studies were conducted at the renowned Scripps Research Institute in the US and a number of other specialist virology laboratories.

The active in VIRALEZE™ (SPL7013) has demonstrated potent antiviral activity against multiple strains of SARS-CoV-2 as well as other respiratory viruses, including cold viruses, influenza, RSV (respiratory syncytial virus), MERS, and SARS.

The antiviral active in VIRALEZE™ (SPL7013) works by irreversibly blocking coronavirus SARS-CoV-2 'spike' proteins from binding to human airway cells.

VIRALEZE™ antiviral nasal spray forms a physical barrier to respiratory viruses in the nasal cavity and has multiple unique advantages, including its virucidal action, its rapid onset (inactivates >99.9% SARS-CoV-2 within one minute, in laboratory studies<sup>1</sup>) and its ability to inactivate virus either before or after exposure<sup>1</sup>.

Dr Jackie Fairley, CEO of Starpharma commented: "We are delighted to be rolling out VIRALEZE™ in Europe following the UK launch. The product has been very well received in the UK, and we hope that VIRALEZE™ will provide European consumers with added peace of mind."

"In addition to making VIRALEZE™ available direct to consumers in Europe via [www.viraleze.co](http://www.viraleze.co), commercial discussions for distribution continue in parallel. Starpharma is actively engaged in discussions with a variety of organisations in the region, including sporting teams, which have expressed interest in VIRALEZE™."

VIRALEZE™ is registered in the EU. Starpharma is pursuing avenues to provide rapid access to VIRALEZE™ in India, including opportunities for expedited registration and distribution in the region. The Company is also progressing regulatory activities for a number of markets, including Australia, with the intention to roll it out across multiple markets.

For more information on VIRALEZE™ visit [www.viraleze.co](http://www.viraleze.co).

---

<sup>1</sup> Paull, J.R.A. et al. Virucidal and antiviral activity of astodrimmer sodium against SARS-CoV-2 in vitro (2021). Available at SSRN: <https://ssrn.com/abstract=3830085>

## About VIRALEZE™ Antiviral Nasal Spray

VIRALEZE™ Antiviral Nasal Spray was developed by Starpharma (ASX: SPL) and is registered for sale in Europe. It is an easy-to-use antiviral nasal spray containing 1% w/w astodimer sodium (SPL7013), shown in laboratory studies to inactivate respiratory viruses, including >99.9% of coronavirus SARS-CoV-2.

VIRALEZE™ binds to and irreversibly inactivates a broad spectrum of respiratory viruses. Inactivated viruses are blocked from attaching to cells inside your nose and taking hold. In addition to providing a protective antiviral barrier, VIRALEZE™ provides a moisturising layer to help keep nasal tissue hydrated, protecting it from dryness and damage.

SPL7013 is included in products that are already approved in >45 countries and available for sale in the UK, Europe, Japan, South East Asia, South Africa, Australia, and New Zealand.

VIRALEZE™ can be used alongside vaccines, masks, and physical distancing.



### Advantages of VIRALEZE™

- Broad-spectrum, works against multiple strains of SARS-CoV-2 and multiple respiratory viruses.
- Potent antiviral activity against multiple strains of SARS-CoV-2.
- Virucidal, irreversibly and rapidly inactivating >99.9% of coronavirus/ SARS-CoV-2 within one minute<sup>2</sup>.
- Ability to inactivate virus either before or after exposure.
- Contains a well-tolerated, already marketed active, which is not absorbed into the bloodstream.
- Provides a moisturising and protective barrier to help keep nasal tissue hydrated.
- Room temperature storage, easy and convenient for regular use.

*Starpharma acknowledges the \$1 million in funding for the development of VIRALEZE™ provided by the Australian Government's Medical Research Future Fund (MRFF) Biomedical Translation Bridge (BTB) Program, with support from UniQuest. Delivered by MTPConnect, the Australian Government's BTB program is a \$22.3 million MRFF initiative that provides up to \$1 million in matched funding to nurture the translation of new therapies, technologies and medical devices through to proof of concept to turn innovative medical ideas into reality.*

---

## About Starpharma

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for COVID-19, DEP® drug delivery and VivaGel®. Starpharma has developed VIRALEZE™, an antiviral nasal spray for COVID-19, which is complementary to vaccines and other preventative measures such as distancing and PPE. VIRALEZE™ is registered for sale in the UK/Europe and available in the UK through LloydsPharmacy. SPL7013 is utilised in approved products - the VivaGel® condom and VivaGel® BV. VivaGel® BV has been licensed in >160 countries, is approved in >45 countries and available for sale in the UK, Europe, Japan, South East Asia, South Africa, Australia and New Zealand.

As a leading company in dendrimer-based drug delivery, Starpharma's proprietary drug delivery platform technology, DEP®, is being used to improve pharmaceuticals, to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP® versions of existing drugs, particularly in the area of anti-cancer therapies. DEP® partnerships include oncology programs with AstraZeneca, with Merck in the area of Antibody Drug Conjugates (ADCs), with Chase Sun in the area of anti-infectives and other world leading pharmaceutical companies. Starpharma's partnered DEP® programs have the potential to generate significant future milestones and royalties.

[Starpharma.com](https://www.starpharma.com) | [Twitter](#) | [LinkedIn](#)

---

<sup>2</sup> SSRN: <https://ssrn.com/abstract=3830085>



**Media: Sumit Media**

Grant Titmus  
Mob: +61 419 388 161  
[grant@sumitmedia.com.au](mailto:grant@sumitmedia.com.au)

**Starpharma Holdings Limited**

Dr Jackie Fairley, Chief Executive Officer  
Nigel Baade, CFO and Company Secretary  
+61 3 8532 2704

[investor.relations@starpharma.com](mailto:investor.relations@starpharma.com)

4-6 Southampton Crescent  
Abbotsford Vic 3067

**Disclosure**

This ASX Announcement was authorised for release by the Chairman, Mr Rob Thomas.

**Forward Looking Statements**

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.